^
    Back
    Association details:
    Biomarker:PDGFRA amplification + KDR amplification
    Cancer:Glioma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Med (Lausanne)
    Title:

    Druggable genomic landscapes of high-grade gliomas

    Published date:
    12/25/2023
    Excerpt:
    Cabozantinib conferred radiographic partial response in two patients harboring a MET and a PDGFRA/KDR amplification.
    DOI:
    10.3389/fmed.2023.1254955